Glaukos Corporation
Glaukos Corporation's Overview
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on leveraging its novel platform technologies to transform the treatment of chronic eye diseases. The company pioneered Micro-Invasive Glaucoma Surgery (MIGS) and continues to innovate with a pipeline of therapies for glaucoma, corneal disorders (including keratoconus), and retinal diseases (such as diabetic macular edema and retinal vein occlusion). Glaukos is committed to improving patient outcomes and advancing the standard of care in ophthalmology worldwide.
Where is Glaukos Corporation's Headquarters?
HQ Function
The headquarters serves as the central command for Glaukos's global operations, including executive leadership, strategic planning, research and development oversight, corporate finance, legal, and global marketing functions.
Notable Features:
Modern campus-style facility designed to foster innovation and collaboration. It likely incorporates advanced R&D laboratories, administrative offices, and spaces conducive to cutting-edge medical technology development.
Work Culture:
The work culture at Glaukos HQ is characterized by innovation, scientific rigor, and a patient-centric approach. Employees are driven by a mission to develop transformative ophthalmic therapies, fostering a dynamic and collaborative environment.
HQ Significance:
The San Clemente headquarters is pivotal for Glaukos's leadership in ophthalmic innovation, particularly its pioneering work in MIGS and development of sustained pharmaceutical delivery systems. It anchors the company's global R&D and commercial strategies.
Values Reflected in HQ: The headquarters reflects Glaukos's core values of innovation, scientific excellence, integrity, and a commitment to improving the lives of patients with eye diseases. The facility's design likely prioritizes functionality for research and development.
Location:
Glaukos Corporation maintains a robust global presence with direct commercial operations in numerous countries, including the United States, Japan, Germany, Australia, Canada, the United Kingdom, and other key European markets. Beyond direct operations, Glaukos utilizes a network of distribution partners to make its products available in many other countries across Asia-Pacific, Europe, Latin America, and the Middle East. Globally supported functions include sales, marketing, clinical research, regulatory affairs, medical affairs, and customer & technical support, ensuring worldwide access to its innovative ophthalmic therapies.
Street Address:
229 Avenida Fabricante
City:
San Clemente
State/Province:
CA
Country:
USA
Glaukos Corporation's Global Presence
Aliso Viejo, CA, USA
Address: 27121 Aliso Viejo Parkway, Aliso Viejo, CA 92656
Leverages Southern California's rich medtech ecosystem for talent and resources, supporting the scaling of production and innovation for Glaukos's global product supply.
Burlington, MA, USA
Address: 201 Burlington Road, Burlington, MA 01803
Acts as a specialized hub for advancing treatments for corneal disorders, benefiting from the strong biotech and medtech cluster in the Greater Boston area.
Düsseldorf, Germany
Address: [Specific street address not readily public, generally located in Düsseldorf]
Facilitates market penetration and growth in the important European ophthalmology market, ensuring compliance with regional regulations and adapting global strategies to local healthcare needs.
Tokyo, Japan
Address: [Specific street address not readily public, generally located in Tokyo]
Drives adoption of Glaukos's innovative therapies in Japan, a significant and technologically advanced healthcare market, catering to the specific needs of Japanese ophthalmologists and patients.
Buying Intent Signals for Glaukos Corporation
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Glaukos Corporation
As of April 2025, Glaukos Corporation' leadership includes:
Investors of Glaukos Corporation
Glaukos Corporation has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Over the past 12-15 months, Glaukos Corporation has strengthened its leadership team with key appointments, including a new Chief Scientific Officer and a new Chief Financial Officer. These changes underscore the company's commitment to advancing its research pipeline and executing its strategic growth objectives in the ophthalmic market.
New Appointments:
Technology (Tech Stack) used by Glaukos Corporation
Discover the tools Glaukos Corporation uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Glaukos Corporation Email Formats and Examples
Glaukos Corporation commonly uses an email format that combines the first initial of an employee's first name with their full last name, followed by the @glaukos.com domain. Variations might exist but this is a widely observed pattern.
flast@glaukos.com (e.g., jsmith@glaukos.com)
Format
jsmith@glaukos.com
Example
85%
Success rate
News and media
Glaukos Corporation Investor Relations • May 2, 2024
Glaukos Corporation Showcases Expanding Portfolio And Presents New Clinical Data At 2024 ASCRS Annual Meeting
Glaukos highlighted its broad and expanding product pipeline and presented new clinical data across its glaucoma, corneal health, and retinal disease franchises at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, underscoring its commitment to innovation in eye care....more
Glaukos Corporation Investor Relations • May 1, 2024
Glaukos Corporation Reports First Quarter 2024 Financial Results
Glaukos announced first quarter 2024 net sales of $85.7 million, marking a 16% increase compared to the same period in the previous year. The company also reaffirmed its full-year 2024 net sales guidance of $350 million to $360 million....more
Glaukos Corporation Investor Relations • February 28, 2024
Glaukos Corporation Announces U.S. Commercial Launch of iDose® TR (travoprost intraocular implant)
Glaukos announced the U.S. commercial launch of iDose® TR, its FDA-approved, long-duration travoprost delivery implant. This innovative therapy is designed for patients with ocular hypertension or open-angle glaucoma and offers continuous drug delivery within the eye....more
Glaukos Corporation Investor Relations • December 14, 2023
Glaukos Corporation Announces FDA Approval of iDose® TR (travoprost intraocular implant)
Glaukos received U.S. Food and Drug Administration (FDA) approval for iDose® TR, a novel, long-duration, intracameral procedural pharmaceutical therapy designed to deliver travoprost continuously for up to 3 years, marking a significant milestone in glaucoma treatment....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Glaukos Corporation, are just a search away.